COMMON AND RARE SEQUENCE VARIANTS IN BREAST CANCER RISK

描述(申请人提供)：结合分离分析和突变筛查研究的数据，已建立的乳腺癌易感基因约占该疾病遗传成分的20%-25%。导致乳腺癌风险的剩余遗传成分的基因和/或序列变异尚未确定。目前对SNPs和单倍型作图的大部分热情都是基于这样的假设，即普通的适度风险变异是最重要的。然而，很少有候选的常见SNP与乳腺癌风险之间的关联被独立复制。因此，这项研究的中心问题是：常见的(通常是中等风险的)序列变异与罕见的(潜在的高风险)序列变异对乳腺癌遗传归因率的相对贡献是什么？U利用1,250例遗传高危乳腺癌病例和1,250例频率匹配的人群对照，我们提出了一项新的研究，旨在对常见疾病/常见变异和常见疾病/罕见变异的遗传易感性模型进行直接比较。这间书房有两只胳膊。首先，我们将用乳腺癌遗传学研究社区在这项研究过程中已知或发现的所有常见序列变异对病例和对照进行分型，以预测乳腺癌风险的增加。在第二个臂中，我们将突变筛选病例和对照中强候选易感基因的开放阅读框。对基因和突变筛查数据的分析应该为中心研究问题提供答案。与没有这些标准的类似规模的研究相比，我们对早期发病和家族性病例的关注将大大提高检测有害序列变异带来的风险的能力。这项研究的结果在三个方面与公众健康相关：(1)这项研究将对似乎适度增加乳腺癌风险的基因及其突变进行假设检验。测量这些基因突变造成的风险是在初步迹象表明该基因在乳腺癌易感性中发挥作用和将该基因应用于癌症遗传学的临床实践之间的关键一步。(2)本研究结果将影响临床肿瘤遗传学的未来发展方向。中等风险和中等风险序列变异对乳腺癌归因风险的相对贡献将对遗传信息如何进入临床实践产生影响。(3)对基因型和突变筛查数据的分析将提供癌症易感性的常见变异和罕见变异遗传模型的风险比较。这是遗传学研究界当前主要感兴趣和重要的问题。如果我们观察到稀有序列变异造成的风险与普通SNPs相同或更大，可能有必要将突变筛查从遗传流行病学/家族学领域扩大到更大规模的基于人群的研究。

DESCRIPTION (provided by applicant): Combining data from segregation analyses and mutation screening studies, the established breast cancer susceptibility genes are responsible for an estimated 20%-25% of the genetic component of this disease. The genes and/or sequence variants responsible for the remaining genetic component of breast cancer risk have yet to be identified. Most of the current enthusiasm for SNPs and haplotype mapping are predicated on the assumption that common modest risk variants are most important. However, few candidate associations between common SNPs and breast cancer risk have been independently reproduced. Thus the central question of this study: What is the relative contribution of common (usually modest-risk) sequence variants vs. rare (potentially higher-risk) sequence variants to the genetic attributable fraction of breast cancer? U Using an ethnically diverse series of 1,250 genetically high-risk breast cancer cases and 1,250 frequency-matched population controls, we propose a novel study designed to make a direct comparison between the common disease/ common variant and common disease/ rare variant models of genetic susceptibility. The study has two arms. In the first, we will genotype the cases and controls with all of the common- sequence variants that are known, or are found over the course of this study by the breast cancer genetics research community, to predict increased risk of breast cancer. In the second arm, we will mutation screen the open reading frames of strong candidate susceptibility genes in both the cases and the controls. Analysis of the genotype and mutation screening data should provide an answer to the central study question. Our focus on early onset and familial cases will substantially increase power to detect risk conferred by deleterious sequence variants as compared to a study of similar size without these criteria, fl Results from this study are relevant to public health in three ways: (1) This study will provide a hypothesis test of genes, and mutations in them, that appear to confer moderately to dramatically increased risk of breast cancer. Measuring risk due to mutations in these genes is a key step that lies between initial indications that the gene plays a role in breast cancer susceptibility and bringing the gene into the clinical practice of cancer genetics. (2) Results from this study will bear on the future direction of clinical cancer genetics. The relative contribution that moderate risk versus modest risk sequence variants make to the attributable risk of breast cancer will have an impact on how the genetic information enters clinical practice. (3) Analysis of the genotype and mutation screening data will provide a comparison of risk attributable to the common variant and rare variant genetic models of cancer susceptibility. This is a question of major current interest and importance within the genetics research community. If we observe that the rare sequence variants account for as much or more risk than do common SNPs, it may be necessary to expand mutation screening from the realm of genetic epidemiology/ family studies into larger scale population-based studies.